Baird Said Road Getting Tougher for Dendreon (DNDN)

Baird commented on Dendreon (NASDAQ: DNDN) following this weekend's ASCO meeting, saying "Provenge's commercial task has become increasingly difficult with full publication of Zytiga's pre-chemo data at ASCO and the anticipated approval/launch of MDV3100."

The analyst said Dendreon's sequencing message is not resonating, and Zytiga
pre-chemo use is already quite measurable.

"With these two agents dominating mindshare for some time to come, we worry Provenge may increasingly struggle to stay relevant," the firm said.

The firm maintained their Neutral with a new price target of $11.00 (from $13.00).

For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.

Shares of Dendreon closed at $6.76 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Freedom Broker Downgrades Karooooo Ltd. (KARO) to Hold
• GE Aerospace (GE) PT Raised to $435 at UBS on Strong Demand
• UnitedHealth Group (UNH) PT Raised to $490 at UBS